Login to Your Account



'Moving in the Tau Direction'

TauRx Launches Pivotal LMTX Program in Pick's, Alzheimer's

By Nuala Moran
Staff Writer

Tuesday, September 11, 2012
LONDON – TauRx Therapeutics Ltd. announced the start of a 180-patient Phase III trial of its tau aggregation inhibitor, LMTX, in Pick's disease, an early onset form of dementia that shows similar characteristics to Alzheimer's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription